Kidney Week

Abstract: FR-PO865

Efficacy and Safety of Telitacicept in IgA Nephropathy: A Real-World Study

Session Information

• IgA Nephropathy: Clinical, Outcomes, and Therapeutics
  October 25, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Dong, Lingqiu, West China Hospital of Sichuan University, Chengdu, Sichuan, China

Lingqiu Dong

• Qin, Wei, West China Hospital of Sichuan University, Chengdu, Sichuan, China

Wei Qin, PhD

Background

IgA nephropathy (IgAN) is the most common primary glomerular disease in the world. Telitacicept is a humanized fusion protein composed of a transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor and human IgG. This study was designed to evaluate the efficacy and safety of telitacicept in patients with IgAN.

Methods

Biopsy-proven IgAN patients with 24-hour proteinuria greater than 0.5 g/day who received telitacicept 240 mg once a week were recruited in this study and 1:1 matched with patients received supportive treatment only or immunosuppressive treatment by propensity score matching. The primary outcome was the change from baseline in 24-hour proteinuria over the 3-month follow-up.

Results

Twenty-one patients in each group were enrolled. The mean eGFR was 80.1 ml/min/1.73m², and the median 24-hour urine protein was 1.48 g/day. At the end of the 3-month follow-up, telitacicept reduced median proteinuria by 0.72 g/d (54.6%) from baseline, compared with a reduction of 0.18 g/d (20%) in the supportive treatment group (P < 0.001), and 1.12 g/d (72.1%) in the immunosuppressive treatment group (P = 0.814). Preserved eGFR levels were observed in the telitacicept group (1.9 ml/min/1.73 m2 [4.3%]), while the eGFR level declined in the supportive treatment group (- 2.9 ml/min/1.73 m² [- 5.8%]) and immunosuppression group (- 6.1 ml/min/1.73 m² [- 8.4%]). No serious adverse events were observed in the telitacicept treatment group. Injection site reactions were more prevalent in the telitacicept group, meanwhile immunosuppression group had more respiratory tract infections.

Conclusion

Telitacicept can reduce proteinuria in patients with IgAN and showed a favourable safety profile.

Figure 1. Participant recruitment and exclusion flowchart.

Figure 2. Changes in proteinuria and eGFR levels from baseline.